These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 36473633)

  • 1. Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trial.
    Beck LA; Bieber T; Weidinger S; Tauber M; Saeki H; Irvine AD; Eichenfield LF; Werfel T; Arlert P; Jiang L; Røpke M; Paller AS
    J Am Acad Dermatol; 2023 Apr; 88(4):816-823. PubMed ID: 36473633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of interleukin-13 signalling improves skin barrier function and biology in patients with moderate-to-severe atopic dermatitis.
    Sander N; Stölzl D; Fonfara M; Hartmann J; Harder I; Suhrkamp I; Jakaša I; van den Bogaard E; van Vlijmen-Willems I; Szymczak S; Rodriguez E; Gerdes S; Weidinger S
    Br J Dermatol; 2024 Aug; 191(3):344-350. PubMed ID: 38531691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials.
    Simpson EL; Pink AE; Blauvelt A; Gooderham M; Armstrong AW; Worm M; Katoh N; Peris K; Puig L; Barbarot S; Mark T; Steffensen LA; Tindberg AM; Wollenberg A
    Am J Clin Dermatol; 2023 Nov; 24(6):939-952. PubMed ID: 37682422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
    Wollenberg A; Blauvelt A; Guttman-Yassky E; Worm M; Lynde C; Lacour JP; Spelman L; Katoh N; Saeki H; Poulin Y; Lesiak A; Kircik L; Cho SH; Herranz P; Cork MJ; Peris K; Steffensen LA; Bang B; Kuznetsova A; Jensen TN; Østerdal ML; Simpson EL;
    Br J Dermatol; 2021 Mar; 184(3):437-449. PubMed ID: 33000465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years.
    Guttman-Yassky E; Kabashima K; Staumont-Salle D; Nahm WK; Pauser S; Da Rosa JC; Martel BC; Madsen DE; Røpke M; Arlert P; Steffensen L; Blauvelt A; Reich K
    Allergy; 2024 Jun; 79(6):1560-1572. PubMed ID: 38563683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skin dysbiosis in the microbiome in atopic dermatitis is site-specific and involves bacteria, fungus and virus.
    Bjerre RD; Holm JB; Palleja A; Sølberg J; Skov L; Johansen JD
    BMC Microbiol; 2021 Sep; 21(1):256. PubMed ID: 34551705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skin microbiome dysbiosis and the role of Staphylococcus aureus in atopic dermatitis in adults and children: A narrative review.
    Demessant-Flavigny AL; Connétable S; Kerob D; Moreau M; Aguilar L; Wollenberg A
    J Eur Acad Dermatol Venereol; 2023 Jun; 37 Suppl 5():3-17. PubMed ID: 37232427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleach baths enhance skin barrier, reduce itch but do not normalize skin dysbiosis in atopic dermatitis.
    Stolarczyk A; Perez-Nazario N; Knowlden SA; Chinchilli E; Grier A; Paller A; Gill SR; De Benedetto A; Yoshida T; Beck LA
    Arch Dermatol Res; 2023 Dec; 315(10):2883-2892. PubMed ID: 37755506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3.
    Blauvelt A; Gooderham M; Bhatia N; Langley RG; Schneider S; Zoidis J; Kurbasic A; Armstrong A; Silverberg JI
    Dermatol Ther (Heidelb); 2022 Nov; 12(11):2499-2516. PubMed ID: 36152216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials.
    Simpson EL; Merola JF; Silverberg JI; Reich K; Warren RB; Staumont-Sallé D; Girolomoni G; Papp K; de Bruin-Weller M; Thyssen JP; Zachariae R; Olsen CK; Wollenberg A
    Br J Dermatol; 2022 Dec; 187(6):888-899. PubMed ID: 36082590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis.
    Merola JF; Bagel J; Almgren P; Røpke MA; Lophaven KW; Vest NS; Grewal P
    J Am Acad Dermatol; 2021 Jul; 85(1):71-78. PubMed ID: 33744356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Staphylococcus aureus colonization and immune defects on the pathogenesis of atopic dermatitis.
    Özdemіr E; Öksüz L
    Arch Microbiol; 2024 Sep; 206(10):410. PubMed ID: 39302484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tralokinumab in Atopic Dermatitis: A Profile of Its Use.
    Blair HA
    Clin Drug Investig; 2022 Apr; 42(4):365-374. PubMed ID: 35316850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin microbiome and its association with host cofactors in determining atopic dermatitis severity.
    Rauer L; Reiger M; Bhattacharyya M; Brunner PM; Krueger JG; Guttman-Yassky E; Traidl-Hoffmann C; Neumann AU
    J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):772-782. PubMed ID: 36433676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-oriented measures for phase 3 studies of tralokinumab for the treatment of atopic dermatitis (ECZTRA 1, 2, and 3).
    Simpson EL; Wollenberg A; Soong W; Steffensen LA; Kurbasic A; Schneider S; Zoidis J; Silverberg JI
    Ann Allergy Asthma Immunol; 2022 Nov; 129(5):592-604.e5. PubMed ID: 35843520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition.
    Simpson EL; Guttman-Yassky E; Eichenfield LF; Boguniewicz M; Bieber T; Schneider S; Guana A; Silverberg JI
    Allergy; 2023 Nov; 78(11):2875-2891. PubMed ID: 37455359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis: A Secondary Analysis.
    Merola JF; Butler DC; Mark T; Schneider S; Kim Y; Abuabara K
    JAMA Dermatol; 2023 Oct; 159(10):1119-1123. PubMed ID: 37610789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis.
    Callewaert C; Nakatsuji T; Knight R; Kosciolek T; Vrbanac A; Kotol P; Ardeleanu M; Hultsch T; Guttman-Yassky E; Bissonnette R; Silverberg JI; Krueger J; Menter A; Graham NMH; Pirozzi G; Hamilton JD; Gallo RL
    J Invest Dermatol; 2020 Jan; 140(1):191-202.e7. PubMed ID: 31252032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysbiotic Lesional Microbiome With Filaggrin Missense Variants Associate With Atopic Dermatitis in India.
    Nath S; Kumari N; Bandyopadhyay D; Sinha N; Majumder PP; Mitra R; Mukherjee S
    Front Cell Infect Microbiol; 2020; 10():570423. PubMed ID: 33282748
    [No Abstract]   [Full Text] [Related]  

  • 20. The influence of treatment in alpine and moderate maritime climate on the composition of the skin microbiome in patients with difficult to treat atopic dermatitis.
    van Mierlo MMF; Totté JEE; Fieten KB; van den Broek TJ; Schuren FHJ; Pardo LM; Pasmans SGMA
    Clin Exp Allergy; 2019 Nov; 49(11):1437-1445. PubMed ID: 31509295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.